Mesothelioma | Mesothelioma

The first poster will report findings regarding the mechanism of action of seliciclib and related follow-on compounds in multiple myeloma cells, a hematologic malignancy.

The second poster will report results of in vitro drug combination studies evaluating on non-small cell Details of the poster presentations and related bibliographical citations are as follows: Monday, April 3, 2006 - Novel cyclin dependent kinase (CDK) inhibitors induce down regulation of Mcl-1 and apoptosis in multiple myeloma cells.

Abstract Number: 2069.

Citation: MacCallum, D.E.

et al.

Novel cyclin dependent kinase (CDK) inhibitors induce down regulation of Mcl-1 and apoptosis in multiple myeloma cells.

Proc.

Amer.

Assoc.

Cancer Res.

2006; 47: 2069.

Tuesday, April 4, 2006 - Combination analysis between seliciclib (CYC202; R-roscovitine) and other molecularly targeted anticancer agents in non-small cell Abstract number: 3838.

Citation: Fleming, I.N., et al.

Combination analysis between seliciclib (CYC202; R-roscovitine) and other molecularly targeted anticancer agents in non-small cell Proc.

Amer.

Assoc.

Cancer Res.

2006; 47: 3838.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage biopharmaceutical company dedicated t...

Read more...